Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: Analysis of a prospective randomized phase III trial
Date
1996Author
Kosmidis, Paraskevas A.Tsavaris, N.
Skarlos, Dimosthenis V.
Theocharis, D.
Samantas, E.
Pavlidis, Nicholas
Briassoulis, E. Ch
Fountzilas, George
Source
Journal of Clinical OncologyVolume
14Issue
10Pages
2682-2687Google Scholar check
Keyword(s):
Metadata
Show full item recordAbstract
Purpose: To investigate if double modulation of fluorouracil (5-FU) with leucovorin (folinic acid [FA]) and interferon alfa-2b (IFN 2b) improves responses and survival in comparison to single modulation of 5-FU with FA. Patients and Methods: One hundred six patients with histologically confirmed advanced colorectal cancer, measurable disease, and without previous chemotherapy were prospectively randomized into two groups. Patients in group A received 5-FU 450 mg/m2 as an intravenous bolus in the midinfusion of FA weekly. FA was given at a dose of 200 mg/m2 in 500 mL 0.9% normal saline solution in 2-hour infusion. Patients in group B received exactly the same regimen plus IFN 2b 5 million units subcutaneously three times weekly. Results: All patients were well balanced in both groups regarding age, sex, performance status, number, and site of metastasis. One hundred two patients were assessable. All patients have died. There was no difference in response between the two groups (7.8% v 9.8%). Median survival was 10.1 months in group A, and 7.2 months in group B (P = .00189). Median time to progression was 8.4 and 5.2 months, respectively (P = .00196). Overall, better performance status and older age had a positive impact on survival. Toxicity was the most important and catastrophic aspect of this study. Patients who received IFN 2b had significantly worse anemia, neutropenia, diarrhea, anorexia, weight loss, flu-like syndrome, and psychological reactions. Conclusion: Based on this final analysis, the addition of IFN 2b to the combination of 5-FU and FA enhances toxicity and contributes to decreased survival.
Collections
Cite as
Related items
Showing items related by title, author, creator and subject.
-
Article
Prognostic factors in patients with colorectal cancer receiving adjuvant chemotherapy or chemoradiotherapy: A pooled analysis of two randomized studies
Bamias, A. T.; Basdanis, G.; Xanthakis, I.; Pavlidis, Nicholas; Fountzilas, George (2005)Background. Although the TNM system is useful in predicting survival in resected colorectal cancer, heterogeneity within the same stages regarding prognosis exists. We are presenting a pooled analysis of prognostic factors ...
-
Article
Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: A randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG)
Skarlos, Dimosthenis V.; Samantas, E.; Briassoulis, E. Ch; Panoussaki, E.; Pavlidis, Nicholas; Kalofonos, H. P.; Kardamakis, D.; Tsiakopoulos, E.; Kosmidis, Paraskevas A.; Tsavdaridis, D.; Tzitzikas, J.; Tsekeris, P.; Kouvatseas, G.; Zamboglou, N.; Fountzilas, George (2001)Background: Concurrent platinum-etoposide chemotherapy given in combination with hyperfractionated thoracic radiation therapy (HTRT) in limited disease (LD) small cell lung cancer (SCLC) is associated with a high response ...
-
Article
Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis
Mauri, D.; Pavlidis, Nicholas; Ioannidis, J. P. A. (2005)Background: Interest in the use of preoperative systemic treatment in the management of breast cancer has increased because such neoadjuvant therapy appears to reduce the extent of local surgery required. We compared the ...